Antiparasitical chemotherapy in Chagas' disease cardiomyopathy: Current evidence

Tropical Medicine and International Health

Volumn 17, Issue 9, 2012, Pages 1057-1065

  Matta Guedes, Paulo Marcos ^a   Gutierrez, Fredy Roberto Salazar ^b   Nascimento, Manuela Sales Lima ^c   Do Valle Matta, Maria Adelaide ^d   Silva, João Santana ^c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^b CENTRO DE INVESTIGACIONES   (Colombia)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cardiac inflammation; Chagas' disease; Chemotherapy; Parasite persistence; Trypanosoma cruzi

Indexed keywords

BENZNIDAZOLE; NIFURTIMOX; NITROFURAN DERIVATIVE; RODANIL; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CHAGAS DISEASE; CHEMOTHERAPY; CHILD; DATA ACQUISITION; DEVELOPMENTAL STAGE; DISEASE SEVERITY; DRUG; ETIOLOGY; MEDICINE; PARASITE PREVALENCE; PARASITOLOGY; PERSISTENCE; PROTOZOAN;

ACUTE DISEASE; ARTICLE; CHAGAS DISEASE; CHRONIC DISEASE; CLINICAL PRACTICE; HEART INJURY; HUMAN; MYOCARDITIS; NONHUMAN; TRYPANOSOMA CRUZI;

ACUTE DISEASE; ANTIPARASITIC AGENTS; CHAGAS CARDIOMYOPATHY; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HUMANS; TRYPANOSOMA CRUZI;

TRYPANOSOMA CRUZI;

EID: 84865553036     PISSN: 13602276     EISSN: 13653156     Source Type: Journal    
DOI: 10.1111/j.1365-3156.2012.03025.x     Document Type: Article

References (63)

1. Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F & Freilij H (2011) Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 127, e212-e218.
2. Andrade SG & Magalhaes JB (1996) Biodemes and zymodemes of Trypanosoma cruzi strains: correlations with clinical data and experimental pathology. Revista da Sociedade Brasileira de Medicina Tropical 30, 27-35.
3. Andrade SG, Magalhaes JB & Pontes AL (1989) Therapy of the chronic phase of the experimental infection by Trypanosoma cruzi with benzonidazole and nifurtimox. Revista da Sociedade Brasileira de Medicina Tropical 22, 113-118.
4. Andrade SG, Freitas LA, Peyrol S, Pimentel AR & Sadigursky M (1991) Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice. Bulletin of the World Health Organization 69, 191-197.
5. Andrade SG, Rassi A, Magalhaes JB, Ferriolli Filho F & Luquetti AO (1992) Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains. Transactions of the Royal Society of Tropical Medicine and Hygiene 86, 624-626.
6. Andrade AL, Martelli CM, Oliveira RM et al. (2004) Short report: benznidazole efficacy among Trypanosoma cruzi-infected adolescents after a six-year follow-up. American Journal of Tropical Medicine and Hygiene 71, 594-597.
7. Andrade JP, Marin Neto JA, Paola AA et al. (2011) I Latin American Guidelines for the diagnosis and treatment of chagas' heart disease: executive summary. Arquivos brasileiros de cardiologia 96, 434-442.
8. Anez N, Carrasco H, Parada H et al. (1999) Myocardial parasite persistence in chronic chagasic patients. The American journal of tropical medicine and hygiene 60, 726-732.
9. Apt W (2010) Current and developing therapeutic agents in the treatment of Chagas disease. Drug design, development and therapy 4, 243-253.
10. Bahia-Oliveira LM, Gomes JA, Cancado JR et al. (2000) Immunological and clinical evaluation of chagasic patients subjected to chemotherapy during the acute phase of Trypanosoma cruzi infection 14-30years ago. The Journal of infectious diseases 182, 634-638.
11. Barbosa AJ, Gobbi H, Lino BT et al. (1986) Comparative study of the conventional method and the peroxidase-antiperoxidase method in the search for tissue parasitism in chronic Chagas' cardiopathy. Revista do Instituto de Medicina Tropical de Sao Paulo 28, 91-96.
12. Bellotti G, Bocchi EA, de Moraes AV et al. (1996) In vivo detection of Trypanosoma cruzi antigens in hearts of patients with chronic Chagas' heart disease. American Heart Journal 131, 301-307.
13. Blanco SB, Segura EL, Cura EN et al. (2000) Congenital transmission of Trypanosoma cruzi: an operational outline for detecting and treating infected infants in north-western Argentina. Tropical Medicine and International Health 5, 293-301.
14. Braga MS, Lauria-Pires L, Arganaraz ER, Nascimento RJ & Teixeira AR (2000) Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives. Revista do Instituto de Medicina Tropical de Sao Paulo 42, 157-161.
15. Brazilian Consensus (2005) Brazilian Consensus on Chagas disease. Revista da Sociedade Brasileira de Medicina Tropical 38 (Suppl. 3), 7-29.
16. Buckner FS & Navabi N (2010) Advances in Chagas disease drug development: 2009-2010. Current opinion in infectious diseases 23, 609-616.
17. Burgos JM, Altcheh J, Petrucelli N et al. (2009) Molecular diagnosis and treatment monitoring of congenital transmission of Trypanosoma cruzi to twins of a triplet delivery. Diagnostic Microbiology and Infectious Disease 65, 58-61.
18. Caldas IS, Talvani A, Caldas S et al. (2008) Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitology Research 103, 413-421.
19. Cancado JR (2002) Long term evaluation of etiological treatment of chagas disease with benznidazole. Revista do Instituto de Medicina Tropical de Sao Paulo 44, 29-37.
20. Chen YT, Brinen LS & Kerr ID (2010) In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi. PLoS Neglected Tropical Diseases 4, 324.
21. Chippaux JP, Clavijo AN, Santalla JA, Postigo JR, Schneider D & Brutus L (2010) Antibody drop in newborns congenitally infected by Trypanosoma cruzi treated with benznidazole. Tropical Medicine and International Health 15, 87-93.
22. de Andrade AL, Zicker F, de Oliveira RM et al. (1996) Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 348, 1407-1413.
23. Dias JC (2006) Chagas disease: successes and challenges. Cadernos de saude publica/Ministerio da Saude, Fundacao Oswaldo Cruz, Escola Nacional de Saude Publica 22, 2020-2021.
24. Docampo R (1990) Sensitivity of parasites to free radical damage by antiparasitic drugs. Chemico-biological interactions 73, 1-27.
25. Docampo R, Moreno SN, Turrens JF, Katzin AM, Gonzalez-Cappa SM & Stoppani AO (1981) Biochemical and ultrastructural alterations produced by miconazole and econazole in Trypanosoma cruzi. Molecular and Biochemical Parasitology 3, 169-180.
26. Escriba JM, Ponce E, Romero Ade D et al. (2009) Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras. Memorias do Instituto Oswaldo Cruz 104, 986-991.
27. Fabbro De Suasnabar D, Arias E, Streiger M et al. (2000) Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients. Revista do Instituto de Medicina Tropical de Sao Paulo 42, 99-109.
28. Fabbro DL, Streiger ML, Arias ED, Bizai ML, del Barco M & Amicone NA (2007) Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21years: parasitological, serological and clinical evolution. Revista da Sociedade Brasileira de Medicina Tropical 40, 1-10.
29. Fernandes CD, Tiecher FM, Balbinot MM et al. (2009) Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up. Memorias do Instituto Oswaldo Cruz 104, 27-32.
30. Ferreira Hde O (1990) Treatment of the undetermined form of Chagas disease with nifortimox and benzonidazole. Revista da Sociedade Brasileira de Medicina Tropical 23, 209-211.
31. Ferreira LR, Abrantes EF, Rodrigues CV et al. (2002) Identification and characterization of a novel mouse gene encoding a Ras-associated guanine nucleotide exchange factor: expression in macrophages and myocarditis elicited by Trypanosoma cruzi parasites. Journal of Leukocyte Biology 72, 1215-1227.
32. Garcia S, Ramos CO, Senra JF et al. (2005) Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations. Antimicrobial Agents and Chemotherapy 49, 1521-1528.
33. Guedes PM, Oliveira FS, Gutierrez FR et al. (2010) Nitric oxide donor trans-[RuCl([15]aneN)NO] as a possible therapeutic approach for Chagas' disease. British Journal of Pharmacology 160, 270-282.
34. Guedes PM, Silva GK, Gutierrez FR & Silva JS (2011) Current status of Chagas disease chemotherapy. Expert Review of Anti-Infective Therapy 9, 609-620.
35. Gutierrez FR, Guedes PM, Gazzinelli RT & Silva JS (2009) The role of parasite persistence in pathogenesis of Chagas heart disease. Parasite Immunology 31, 673-685.
36. Higuchi ML (1995) Chagas disease. Importance of the parasite in the pathogenesis of the cardiac chronic disease. Arquivos brasileiros de cardiologia 64, 251-254.
37. Higuchi ML, De Brito T & Reis MM (1993) Correlation between T.cruzi parasitism and myocardial inflammatory infiltrate in human chronic chagasic myocarditis: light microscopy and immunohistochemical findings. Cardiovascular Pathology 2, 101-106.
38. Higuchi Y, Otsu K, Nishida K et al. (2003) The small GTP-binding protein Rac1 induces cardiac myocyte hypertrophy through the activation of apoptosis signal-regulating kinase 1 and nuclear factor-kappa B. Journal of Biological Chemistry 278, 20770-20777.
39. Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL & McCurley TL (1993) Amplification of a Trypanosoma cruzi DNA sequence from inflammatory lesions in human chagasic cardiomyopathy. American Journal of Tropical Medicine and Hygiene 48, 348-357.
40. Krettli AU & Brener Z (1982) Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. Journal of immunology 128, 2009-2012.
41. Lana M, Lopes LA, Martins HR et al. (2009) Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment. Memorias do Instituto Oswaldo Cruz 104, 1139-1147.
42. Lauria-Pires L, Braga MS, Vexenat AC et al. (2000) Progressive chronic Chagas heart disease ten years after treatment with anti-Trypanosoma cruzi nitroderivatives. The American journal of tropical medicine and hygiene 63, 111-118.
43. Leon JS, Wang K & Engman DM (2003) Myosin autoimmunity is not essential for cardiac inflammation in acute Chagas' disease. Journal of Immunology 171, 4271-4277.
44. Marin-Neto JA, Rassi A Jr, Morillo CA et al. (2008) Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). American Heart Journal 156, 37-43.
45. Olivieri BP, Molina JT, de Castro SL et al. (2010) A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease. International Journal of Antimicrobial Agents 36, 79-83.
46. OPAS (2007) Organizacion Panamericana de la Salud. Reporte sobre la enfermedad de Chagas. Grupo de trabajo científico sobre la enfermedad de Chagas. Reunión Técnica, Buenos Aires, Argentina: Programa Especial de Investigaciones y Enseñanzassobre Enfermedades tropicales. TDR/GTC/09, 266.
47. Pinto Dias JC (1995) Natural history of Chagas disease. Arquivos Brasileiros de Cardiologia 65, 359-366.
48. Prata A (2001) Clinical and epidemiological aspects of Chagas disease. The Lancet Infectious Diseases 1, 92-100.
49. Rassi A Jr, Rassi A & Marin-Neto JA (2010) Chagas disease. Lancet 375, 1388-1402.
50. Russomando G, de Tomassone MM, de Guillen I et al. (1998) Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction. American Journal of Tropical Medicine and Hygiene 59, 487-491.
51. Salvatella R (2007) Andean subregional Chagas disease area and the Andean initiative of Chagas disease. Memorias do Instituto Oswaldo Cruz 102 (Suppl. 1), 39-40.
52. Schijman AG, Altcheh J, Burgos JM et al. (2003) Aetiological treatment of congenital Chagas' disease diagnosed and monitored by the polymerase chain reaction. Journal of Antimicrobial Chemotherapy 52, 441-449.
53. Shikanai-Yasuda MA, Lopes MH, Tolezano JE et al. (1990) Acute Chagas' disease: transmission routes, clinical aspects and response to specific therapy in diagnosed cases in an urban center. Revista do Instituto de Medicina Tropical de Sao Paulo 32, 16-27.
54. Silveira AC (2000) Current situation with chagas disease vector control in the Americas. Cadernos de saúde pública 16 (Suppl. 2), 35-42.
55. Sosa Estani S & Segura EL (1999) Treatment of Trypanosoma cruzi infection in the undetermined phase. Experience and current guidelines of treatment in Argentina. Memorias do Instituto Oswaldo Cruz 94 (Suppl. 1), 363-365.
56. Sosa Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM & Yampotis C (1998) Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. American Journal of Tropical Medicine and Hygiene 59, 526-529.
57. Streiger ML, del Barco ML, Fabbro DL, Arias ED & Amicone NA (2004) Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina. Revista da Sociedade Brasileira de Medicina Tropical 37, 365-375.
58. Tafuri WL (1987) Pathogenesis of Chagas' disease. Revista do Instituto de Medicina Tropical de Sao Paulo 29, 194-199.
59. Urbina JA (2002) Chemotherapy of Chagas disease. Current Pharmaceutical Design 8, 287-295.
60. Viotti R, Vigliano C, Armenti H & Segura E (1994a) Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up. American heart journal 127, 151-162.
61. Viotti R, Vigliano C, Lococo B et al. (2006) Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Annals of Internal Medicine 144, 724-734.
62. Wilson WD, Tanious FA & Mathis A (2008) Antiparasitic compounds that target DNA. Biochimie 90, 999-1014.
63. Zingales B, Andrade SG, Briones MR et al. (2009) A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI. Memorias do Instituto Oswaldo Cruz 104, 1051-1054.